Endothelin receptor antagonists in chronic kidney disease

0
Endothelin receptor antagonists in chronic kidney disease
  • Yanagisawa, M. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411–415 (1988).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Sakurai, T. et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348, 732–735 (1990).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Arai, H., Hori, S., Aramori, I., Ohkubo, H. & Nakanishi, S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348, 730–732 (1990).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Davenport, A. P. et al. Endothelin. Pharmacol. Rev. 68, 357–418 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kohan, D. E., Rossi, N. F., Inscho, E. W. & Pollock, D. M. Regulation of blood pressure and salt homeostasis by endothelin. Physiol. Rev. 91, 1–77 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Karet, F. & Davenport, A. Comparative quantification of endothelin receptor mRNA in human kidney: new tools for direct investigation of human tissue. J. Cardiovasc. Pharmacol. 26, S268–S271 (1995).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Karet, F. E., Kuc, R. E. & Davenport, A. P. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 44, 36–42 (1993).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kohan, D. E. & Barton, M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 86, 896–904 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • de Zeeuw, D. et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 25, 1083–1093 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Heerspink, H. J. L. et al. Atrasentan in patients with IgA nephropathy. N. Engl. J. Med. (2024).

  • Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937–1947 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Trachtman, H. et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J. Am. Soc. Nephrol. 29, 2745–2754 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Heerspink, H. J. L. et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401, 1584–1594 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Rovin, B. H. et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402, 2077–2090 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kedzierski, R. M. & Yanagisawa, M. Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 41, 851–876 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Goddard, J. et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure. Circulation 109, 1186–1193 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Goddard, J. et al. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J. Am. Soc. Nephrol. 15, 2601–2610 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Dhaun, N. et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57, 772–779 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Daehn, I. et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J. Clin. Invest. 124, 1608–1621 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rabelink, T. J. et al. Heparanase: roles in cell survival, extracellular matrix remodelling and the development of kidney disease. Nat. Rev. Nephrol. 13, 201–212 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ebefors, K. et al. Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells. Kidney Int. 96, 957–970 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Garsen, M. et al. Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx. J. Am. Soc. Nephrol. 27, 3545–3551 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Barton, M. & Sorokin, A. Endothelin and the glomerulus in chronic kidney disease. Semin. Nephrol. 35, 156–167 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sorokin, A. & Kohan, D. E. Physiology and pathology of endothelin-1 in renal mesangium. Am. J. Physiol. Renal Physiol. 285, 579–589 (2003).

    Article 

    Google Scholar 

  • Simonson, M. S. & Ismail-Beigi, F. Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J. Biol. Chem. 286, 11003–11008 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Komers, R. & Plotkin, H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 310, R877–884 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Benigni, A. Tubulointerstitial disease mediators of injury: the role of endothelin. Nephrol. Dial. Transplant. 15, 50–52 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lehrke, I., Waldherr, R., Ritz, E. & Wagner, J. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J. Am. Soc. Nephrol. 12, 2321–2329 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Gerstung, M., Roth, T., Dienes, H. P., Licht, C. & Fries, J. W. U. Endothelin-1 induces NF-κB via two independent pathways in human renal tubular epithelial cells. Am. J. Nephrol. 27, 294–300 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zoja, C. et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am. J. Kidney Dis. 26, 934–941 (1995).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zager, R. A., Johnson, A. C. M., Andress, D. & Becker, K. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int. 84, 703–712 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lai, K. N. et al. IgA nephropathy. Nat. Rev. Dis. Prim. 2, 1–20 (2016).

    Google Scholar 

  • Nakamura, T., Ebihara, I., Fukui, M., Tomino, Y. & Koide, H. Effect of a specific endothelin receptor A antagonist on glomerulonephritis of ddY mice with IgA nephropathy. Nephron 72, 454–460 (1996).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Cox, J. et al. Human renal mesangial cell activation induced by endothelin-1 or IgA nephropathy patient-derived immune complexes is blocked by selective eta antagonist atrasentan. Kidney Int. Rep. 6, S160–S161 (2021).

    Article 

    Google Scholar 

  • King, A. et al. Selective ETA antagonist atrasentan, rapidly reduces albuminuria and downregulates intra-renal pro-inflammatory and pro-fibrotic transcriptional networks in the gddY mouse model of spontaneous IgA nephropathy. Kidney Int. Rep. 6, S164 (2021).

    Article 

    Google Scholar 

  • Olson, E. et al. Selective endothelin a receptor antagonist atrasentan attenuates mesangial cell injury, proteinuria and intra-renal proliferative, inflammatory and fibrotic transcriptional networks in a rat model of mesangioproliferative glomerulonephritis. Nephrol. Dial. Transplant. 37, gfac067.063 (2022).

    Article 

    Google Scholar 

  • Olson, N., McConnell, M. & McCown, P. Single nuclei RNA-Seq reveals cell-type specific responses to disease and enalapril in the gddY mouse model of IgA nephropathy. ASN Kidney Week Abstract: TH-PO419 (2022).

  • Nagasawa, H. et al. Sparsentan, the dual endothelin angiotensin receptor antagonist (DEARA), attenuates albuminuria and protects from the development of renal injury to a greater extent than losartan in the GDDY mouse model of IGA nephropathy: a 16-week study. Nephrol. Dial. Transplant. 37, gfac067.060 (2022).

    Article 

    Google Scholar 

  • Reily, C. et al. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy. Am. J. Physiol. Renal Physiol. 326, F862–F875 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chen, H. et al. Plasma and urinary endothelin‐1 in focal segmental glomerulosclerosis. J. Clin. Lab. Anal. 15, 59–63 (2001).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • van de Lest, N. A. et al. Endothelial endothelin receptor A expression is associated with podocyte injury and oxidative stress in patients with focal segmental glomerulosclerosis. Kidney Int. Rep. 6, 1939–1948 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Daehn, I., Yu, L. & Yi, Z. Podocyte-derived endothelin-1 and cross-talk with endothelial cells through EdnrA is essential for glomerular injury. ASN Kidney Week Abstract: FR-OR101 (2023).

  • Gyarmati, G., Deepak, S. & Shroff, U. Sparsentan improves glomerular endothelial and podocyte functions and augments protective tissue repair in a mouse model of focal segmental glomerulosclerosis. ASN Kidney Week Abstract: FR-OR56 (2022).

  • Bedard, P., Jenkinson, C. & Komers, R. Sparsentan protects the glomerular basement membrane and glycocalyx, and attenuates proteinuria in a rat model of focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 37, MO255 (2022).

    Article 

    Google Scholar 

  • Benigni, A. et al. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47, 450–456 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zoja, C. et al. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. Exp. Nephrol. 6, 121–131 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Delimont, D. et al. Laminin α2-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis. PLoS ONE 9, e99083 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Dufek, B. et al. Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease. Kidney Int. 90, 300–310 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cosgrove, D. et al. Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. J. Pathol. 260, 353–364 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Schneider, J. G. et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am. J. Hypertens. 15, 967–972 (2002).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Sasser, J. M. et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J. Am. Soc. Nephrol. 18, 143–154 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hocher, B. et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87, 161–169 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lenoir, O. et al. Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 25, 1050–1062 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Boels, M. G. S. et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. Diabetes 65, 2429–2439 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kim, J. A., Montagnani, M., Kwang, K. K. & Quon, M. J. Reciprocal relationships between insulin resistance and endothelial dysfunction. Circulation 113, 1888–1904 (2006).

    Article 
    PubMed 

    Google Scholar 

  • Khan, M. A. et al. Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Nephron 83, 261–267 (1999).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Minchenko, A. G. et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J. 17, 1–18 (2003).

    Article 

    Google Scholar 

  • Cosenzi, A. et al. Nephroprotective effect of bosentan in diabetic rats. J. Cardiovasc. Pharmacol. 42, 752–756 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ding, S. S. et al. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J. Cardiovasc. Pharmacol. 42, 48–54 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kohan, D. E., Cleland, J. G., Rubin, L. J., Theodorescu, D. & Barton, M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 91, 528–539 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Veenit, V. et al. The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan. Nephrol. Dial. Transplant. 38, 2289–2297 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vergara, A. et al. Enhanced cardiorenal protective effects of combining SGLT2 inhibition, endothelin receptor antagonism and RAS blockade in type 2 diabetic mice. Int. J. Mol. Sci. 23, 12823 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kohan, D. E. et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J. Am. Soc. Nephrol. 22, 763 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wenzel, R. R. et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 20, 655–664 (2009).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mann, J. F. E. et al. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Smolander, J. et al. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin. Pharmacol. Ther. 85, 628–634 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Heerspink, H. J. et al. People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action. Lancet Diabetes Endocrinol. 11, 536–540 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • A study of the effect and safety of sparsentan in the treatment of patients with IgA nephropathy (PROTECT). US National Library of Medicine. ClinicalTrials.gov (2024).

  • Atrasentan in patients with IgA nephropathy (ALIGN). US National Library of Medicine. ClinicalTrials.gov (2024).

  • Heerspink, H. J. L. et al. The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial. J. Clin. Soc. Nephrol. (2024).

    Article 

    Google Scholar 

  • Randomized, double-blind, safety and efficacy study of RE-021 (sparsentan) in focal segmental glomerulosclerosis (DUET). US National Library of Medicine. ClinicalTrials.gov (2024).

  • Rheault, M. N. et al. Sparsentan versus Irbesartan in focal segmental glomerulosclerosis. N. Engl. J. Med. 389, 2436–2445 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Atrasentan in patients with proteinuric glomerular diseases (AFFINITY). US National Library of Medicine. ClinicalTrials.gov (2024).

  • Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Wheeler, D. C. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 22–31 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Heerspink, H. J. L., Kohan, D. E. & de Zeeuw, D. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney Int. 99, 346–349 (2020).

    Article 
    PubMed 

    Google Scholar 

  • Heerspink, H. J. L. et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 402, 2004–2017 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Heerspink, H. J. L. et al. Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial. Nephrol. Dial. Transplant. 39, 414–425 (2023).

    Article 
    PubMed Central 

    Google Scholar 

  • Study to investigate efficacy, safety, and tolerability of zibotentan/dapagliflozin compared to dapagliflozin in participants with chronic kidney disease and high proteinuria (ZENITH high proteinuria). US National Library of Medicine. ClinicalTrials.gov (2024).

  • Randomized, double-blind, placebo-controlled, crossover study of atrasentan in subjects with IgA nephropathy (ASSIST). US National Library of Medicine. ClinicalTrials.gov (2024).

  • Ambrisentan sotagliflozin and prevention of renal injury; a randomized evaluation (ASPIRE). US National Library of Medicine. ClinicalTrials.gov (2023).

  • A study to investigate safety and effect of sparsentan in combination with SGLT2 inhibition in participants with IgAN. US National Library of Medicine. ClinicalTrials.gov (2024).

  • Bugaj, V., Mironova, E., Kohan, D. E. & Stockand, J. D. Collecting duct-specific endothelin b receptor knockout increases ENaC activity. Am. J. Physiol. Cell Physiol. 302, 188–194 (2012).

    Article 

    Google Scholar 

  • Bugaj, V. et al. Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct. Am. J. Physiol. Renal Physiol. 295, 1063–1070 (2008).

    Article 

    Google Scholar 

  • Stuart, D. et al. Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion. BMC Nephrol. 13, 166 (2012).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Stuart, D., Chapman, M., Rees, S., Woodward, S. & Kohan, D. E. Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention. J. Pharmacol. Exp. Ther. 346, 182–189 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Yu, H. et al. The role of venous capacity in fluid retention with endothelin A antagonism: mathematical modelling of the RADAR trial. Br. J. Pharmacol. 181, 4693–4707 (2024).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Galiè, N., Hoeper, M. M., Gibbs, J. S. R. & Simonneau, G. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur. Respir. J. 37, 475–476 (2011).

    Article 
    PubMed 

    Google Scholar 

  • Owen, K., Cross, D. M., Derzi, M., Horsley, E. & Stavros, F. L. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension. Regul. Toxicol. Pharmacol. 64, 95–103 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lepist, E. I. et al. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes. PLoS ONE 9, e87548 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wei, A. et al. Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J. Am. Heart Assoc. 5, e003896 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kohan, D. E., Liew, A., Tang, S. C. W., Barratt, J. & Heerspink, H. J. L. Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes. Metab. 25, 2410–2412 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pena, M. J. et al. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes Obes. Metab. 19, 749–753 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Andress, D. L. et al. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci. 91, 739–742 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Dhaun, N. et al. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J. Am. Soc. Nephrol. 24, 31–36 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pinto-Sietsma, S. J. & Paul, M. A role for endothelin in the pathogenesis of hypertension: fact or fiction? Kidney Int. 54, S115–S121 (1998).

    Article 

    Google Scholar 

  • Iglarz, M. & Schiffrin, E. L. Role of endothelin-1 in hypertension. Curr. Hypertens. Rep. 5, 144–148 (2003).

    Article 
    PubMed 

    Google Scholar 

  • Akter, S. et al. Higher circulatory level of endothelin-1 in hypertensive subjects screened through a cross-sectional study of rural Bangladeshi women. Hypertens. Res. 38, 208–212 (2014).

    Article 
    PubMed 

    Google Scholar 

  • Kostov, K., Blazhev, A., Atanasova, M. & Dimitrova, A. Serum concentrations of endothelin-1 and matrix metalloproteinases-2, -9 in pre-hypertensive and hypertensive patients with type 2 diabetes. Int. J. Mol. Sci. 17, 1182 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kostov, K. & Blazhev, A. Circulating levels of endothelin-1 and big endothelin-1 in patients with essential hypertension. Pathophysiology 28, 489–495 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kostov, K. & Kim, J. The causal relationship between endothelin-1 and hypertension: focusing on endothelial dysfunction, arterial stiffness, vascular remodeling, and blood pressure regulation. Life 11, 986 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Krum, H., Viskoper, R., Lacourciere, Y., Budde, M. & Charlon, V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N. Engl. J. Med. 338, 784–791 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Weber, M. A. et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374, 1423–1431 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Bakris, G. L. et al. Divergent results using clinic and ambulatory blood pressures. Hypertension 56, 824–830 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Schlaich, M. P. et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 400, 1927–1937 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Davison, S. N., Koncicki, H. & Brennan, F. Pain in chronic kidney disease: a scoping review. Semin. Dial. 27, 188–204 (2014).

    Article 
    PubMed 

    Google Scholar 

  • Naidoo, V., Naidoo, S., Mahabeer, R. & Raidoo, D. M. Cellular distribution of the endothelin system in the human brain. J. Chem. Neuroanat. 27, 87–98 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Smith, T. P., Haymond, T., Smith, S. N. & Sweitzer, S. M. Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. J. Pain. Res. 7, 531–545 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hans, G., Deseure, K. & Adriaensen, H. Endothelin-1-induced pain and hyperalgesia: a review of pathophysiology, clinical manifestations and future therapeutic options. Neuropeptides 42, 119–132 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pomonis, J. D., Rogers, S. D., Peters, C. M., Ghilardi, J. R. & Mantyh, P. W. Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J. Neurosci. 21, 999–1006 (2001).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Khodorova, A., Montmayeur, J. P. & Strichartz, G. Endothelin receptors and pain. J. Pain. 10, 4–28 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Motta, E. M., Chichorro, J. G. & Rae, G. A. Role of ETA and ETB endothelin receptors on endothelin-1-induced potentiation of nociceptive and thermal hyperalgesic responses evoked by capsaicin in rats. Neurosci. Lett. 457, 146–150 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • D’Amico, M., Di Filippo, C. & Rossi, F. Selective and non-selective et antagonists reveal an ETA/ETB receptor mediated ET-1-induced antinociceptive effect in PAG area of mice. Life Sci. 61, PL397–PL401 (1997).

    Google Scholar 

  • Hans, G., Deseure, K., Robert, D. & De Hert, S. Neurosensory changes in a human model of endothelin-1 induced pain: a behavioral study. Neurosci. Lett. 418, 117–121 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Chan, K. W. et al. Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease. Kidney Int. 104, 1219–1226 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Rossing, P. et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 102, S1–S127 (2022).

    Article 

    Google Scholar 

  • Dolinina, J., Rippe, A. & Öberg, C. M. Sustained, delayed, and small increments in glomerular permeability to macromolecules during systemic ET-1 infusion mediated via the ETA receptor. Am. J. Physiol. Renal Physiol. 316, F1173–F1179 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kuro, T. et al. Selective antagonism of the ETA receptor, but not the ETB receptor, is protective against ischemic acute renal failure in rats. Jpn. J. Pharmacol. 82, 307–316 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Forbes, J. M., Hewitson, T. D., Becker, G. J. & Jones, C. L. Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int. 59, 1333–1341 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Liss, P., Carlsson, P. O., Nygren, A., Palm, F. & Hansell, P. Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia. Acta Radiol. 44, 111–117 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Abu-Saleh, N. et al. Involvement of the endothelin and nitric oxide systems in the pathogenesis of renal ischemic damage in an experimental diabetic model. Life Sci. 91, 669–675 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Helmy, M. M., Helmy, M. W., Abd Allah, D. M., Abo Zaid, A. M. & Mohy El-Din, M. M. Selective ETA receptor blockade protects against cisplatin-induced acute renal failure in male rats. Eur. J. Pharmacol. 730, 133–139 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • De Miguel, C. et al. Endothelin receptor-specific control of endoplasmic reticulum stress and apoptosis in the kidney. Sci. Rep. 7, 1–13 (2017).

    Article 

    Google Scholar 

  • Colafella, K. M. M. et al. Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats. Cardiovasc. Res. 116, 1779–1790 (2020).

    Article 
    CAS 

    Google Scholar 

  • Harvey, T. W., Engel, J. E. & Chade, A. R. Vascular endothelial growth factor and podocyte protection in chronic hypoxia: effects of endothelin-A receptor antagonism. Am. J. Nephrol. 43, 74–84 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Shimizu, T., Hata, S., Kuroda, T., Mihara, S. I. & Fujimoto, M. Different roles of two types of endothelin receptors in partial ablation-induced chronic renal failure in rats. Eur. J. Pharmacol. 381, 39–49 (1999).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Chade, A. R., Stewart, N. J. & Peavy, P. R. Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease. Kidney Int. 85, 833–844 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Chade, A. R., Tullos, N., Stewart, N. J. & Surles, B. Endothelin-A receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease. J. Am. Soc. Nephrol. 26, 1071–1080 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Saleh, M. A., Pollock, J. S. & Pollock, D. M. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J. Pharmacol. Exp. Ther. 338, 263–270 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Braun, C. et al. Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist. Transplantation 68, 739–746 (1999).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Braun, C. et al. Treatment with a combined endothelin A/B-receptor antagonist does not prevent chronic renal allograft rejection in rats. J. Cardiovasc. Pharmacol. 36, 428–437 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kasztan, M. et al. Long-term endothelin-A receptor antagonism provides robust renal protection in humanized sickle cell disease mice. J. Am. Soc. Nephrol. 28, 2443–2458 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • link

    Leave a Reply

    Your email address will not be published. Required fields are marked *